BrainTale, a medtech deciphering white matter to enable better brain care, spin-off of the Paris Region Greater Hospitals, presented preliminary results during the European Academy of Neurology (Budapest, July 1 – 4, 2023) and the World Parkinson congress (Barcelona, July 4 – 7, 2023) demonstrating the interest of its digital […]
Trending News
IQVIA and the NBA Selected for Abbott’s UNIVANTS of Healthcare Excellence Award
IQVIA, one of the world’s leading providers of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced an initiative to support the league, along with the National Basketball Association and partners at Harvard University, Columbia University and the Bioreference Institute. announced that it was […]
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
Amneal Pharmaceuticals, Inc. announced the launch of its authorized generic for Xyrem®1 oral solution CIII in the United States. Sodium Oxybate oral solution, 0.5 g/mL is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with […]
Acadia Healthcare Forms Joint Venture Partnership with SolutionHealth in New Hampshire
Healthcare company Acadia, Inc. announced that it has formed a joint venture with SolutionHealth to build a state-of-the-art, 144-bed behavioral health hospital in southeastern New Hampshire to address growing and unmet need. for accessible, high-quality behavioral health services in the state. This partnership expands Acadia’s acute services reach to a new […]
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa
Aldeyra Therapeutics, Inc., a biotechnology company dedicated to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced overall positive results from Phase 2 clinical trial of ADX Intravitreal -2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa. Compared to baseline, the clinical trial […]
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
Vertex Pharmaceutical Corporation and Lonza announced a strategic partnership to support the production of Vertex’s portfolio of radically different insulin-producing stem cell therapies for people with T1D, currently focusing on into the VX-880 and VX-264 programs currently in clinical trials. Vertex’s first clinical program, VX-880, demonstrated the clinical proof of concept. […]
B.E.S.T. Program, Simply Healthcare Partner to Expand Healthcare Workforce
Simply Healthcare Plans (Simply) announced a donation of $75,000 to the Tampa Bay-based non-profit, Brain Expansions Scholastic Training (B.E.S.T), to support the organization’s Healthcare Entry Careers and Economic Mobility Initiative. The funding will expand the initiative’s medical skills training and mentorship offerings to underrepresented minority (URM) students to help increase […]
Viz.ai Wins Comparably Awards for Best Place to Work for Second Year
Viz.ai, the leader in AI-powered smart care coordination and disease detection, has been named Comparable Best Place to Work for two years in a row. The company received two Relative Best Workplace awards for best business outlook and best management team in 2023. “We are honored that Viz.ai has received […]
Swiss American CDMO partners with BioNTX to launch the Biotechnology and Healthcare Industry Alliance of North Texas
Swiss American CDMO and BioNTX have partnered to host the inaugural Biotechnology and Healthcare Industry Alliance of North Texas (BHIANT) launch meeting that will champion a next generation, industry-led, workforce partnership. DFW area employers will benefit from a skilled labor force that serves communities by creating pathways to high-paying, quality jobs in biotechnology, […]
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 for Prader-Willi Syndrome
Acadia Pharmaceuticals Inc. announced the addition of a new candidate in Phase 3 development to its rare disease treatment system, ACP-101, for the treatment of hyperphagia in Prader-Willi syndrome (PWS). Acadia acquired the worldwide development and commercialization rights to ACP-101 with the acquisition of Levo Therapeutics in June 2022. “Acadia’s […]
